News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
713,189 Results
Type
Article (42256)
Company Profile (436)
Press Release (670497)
Multimedia
Podcasts (76)
Webinars (13)
Section
Business (208711)
Career Advice (2021)
Deals (36003)
Drug Delivery (104)
Drug Development (83566)
Employer Resources (173)
FDA (16421)
Job Trends (15091)
News (352742)
Policy (33070)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2642)
Accelerated approval (6)
Adcomms (24)
Allergies (84)
Alliances (50930)
ALS (92)
Alzheimer's disease (1420)
Antibody-drug conjugate (ADC) (127)
Approvals (16409)
Artificial intelligence (257)
Autoimmune disease (24)
Automation (15)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (18)
Biosimilars (105)
Biotechnology (330)
Bladder cancer (65)
Brain cancer (26)
Breast cancer (270)
Cancer (2143)
Cardiovascular disease (179)
Career advice (1687)
Career pathing (29)
CAR-T (150)
Cell therapy (426)
Cervical cancer (19)
Clinical research (67634)
Collaboration (838)
Compensation (516)
Complete response letters (24)
COVID-19 (2642)
CRISPR (42)
C-suite (235)
Cystic fibrosis (105)
Data (2083)
Decentralized trials (2)
Denatured (27)
Depression (47)
Diabetes (261)
Diagnostics (6408)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (105)
Drug shortages (26)
Duchenne muscular dystrophy (98)
Earnings (87578)
Editorial (39)
Employer branding (21)
Employer resources (147)
Events (115448)
Executive appointments (712)
FDA (17626)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (754)
Gene editing (109)
Generative AI (20)
Gene therapy (312)
GLP-1 (737)
Government (4493)
Grass and pollen (4)
Guidances (51)
Healthcare (19143)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (123)
Indications (27)
Infectious disease (2785)
Inflammatory bowel disease (140)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (92)
Interviews (311)
IPO (16776)
IRA (43)
Job creations (3699)
Job search strategy (1434)
Kidney cancer (9)
Labor market (36)
Layoffs (489)
Leadership (17)
Legal (7982)
Liver cancer (73)
Lung cancer (309)
Lymphoma (141)
Machine learning (5)
Management (58)
Manufacturing (291)
MASH (65)
Medical device (13495)
Medtech (13500)
Mergers & acquisitions (19738)
Metabolic disorders (691)
Multiple sclerosis (77)
NASH (19)
Neurodegenerative disease (97)
Neuropsychiatric disorders (30)
Neuroscience (1964)
NextGen: Class of 2025 (6755)
Non-profit (4546)
Northern California (2565)
Now hiring (38)
Obesity (376)
Opinion (222)
Ovarian cancer (75)
Pain (84)
Pancreatic cancer (81)
Parkinson's disease (153)
Partnered (21)
Patents (225)
Patient recruitment (100)
Peanut (47)
People (58594)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21249)
Phase II (29842)
Phase III (22072)
Pipeline (1140)
Policy (138)
Postmarket research (2601)
Preclinical (9069)
Press Release (67)
Prostate cancer (101)
Psychedelics (37)
Radiopharmaceuticals (261)
Rare diseases (396)
Real estate (6014)
Recruiting (66)
Regulatory (22668)
Reports (46)
Research institute (2415)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (73)
Series A (134)
Series B (87)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2220)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (29)
Startups (3758)
State (2)
Stomach cancer (14)
Supply chain (66)
Tariffs (24)
The Weekly (47)
United States (22597)
Vaccines (688)
Venture capitalists (40)
Weight loss (250)
Women's health (36)
Worklife (16)
Date
Today (33)
Last 7 days (496)
Last 30 days (2425)
Last 365 days (33905)
2025 (9472)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (57)
Alaska (7)
Arizona (237)
Arkansas (14)
Asia (39170)
Australia (6524)
California (5914)
Canada (1952)
China (500)
Colorado (260)
Connecticut (275)
Delaware (137)
Europe (85582)
Florida (864)
Georgia (203)
Idaho (57)
Illinois (531)
India (25)
Indiana (304)
Iowa (10)
Japan (151)
Kansas (105)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (877)
Massachusetts (4514)
Michigan (217)
Minnesota (384)
Mississippi (2)
Missouri (79)
Montana (29)
Nebraska (25)
Nevada (60)
New Hampshire (66)
New Jersey (1693)
New Mexico (30)
New York (1674)
North Carolina (1003)
North Dakota (7)
Northern California (2565)
Ohio (197)
Oklahoma (14)
Oregon (37)
Pennsylvania (1320)
Puerto Rico (11)
Rhode Island (31)
South America (1110)
South Carolina (20)
South Dakota (1)
Southern California (2220)
Tennessee (99)
Texas (880)
Utah (174)
Virginia (140)
Washington D.C. (61)
Washington State (552)
West Virginia (3)
Wisconsin (52)
713,189 Results for "vividion therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
April 3, 2025
·
5 min read
Press Releases
Vividion Therapeutics Announces Promotion of Jean Bemis to Chief Operating Officer
January 22, 2025
·
3 min read
Press Releases
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
January 8, 2025
·
6 min read
Biotech Beach
Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN)
Vividion Therapeutics, Inc. today announced a landmark publication in Nature.
April 25, 2024
·
4 min read
Bio NC
Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion Therapeutics Agreement includes the discovery and enhancement of targeted oncology drug targets and biomarkers, in addition to positioning existing compounds
Tavros Therapeutics, Inc., a precision oncology platform company, announced that the Company has achieved two milestone payments in its collaboration with Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG.
May 14, 2024
·
3 min read
Press Releases
Vividion Therapeutics Appoints Frank Poschen to Board of Directors
October 8, 2024
·
3 min read
Drug Development
Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor
Vividion Therapeutics, Inc., announced that it has initiated dosing of patients in a Phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced solid and hematologic tumors.
February 6, 2024
·
6 min read
Vividion Therapeutics Recognized as a San Diego area ‘Top Workplaces 2023’ Award Winner by the San Diego Union-Tribune
Vividion Therapeutics, Inc. has been recognized as a Top Workplaces 2023 award winner by the San Diego Union-Tribune for the second year in a row.
November 21, 2023
·
4 min read
Business
Vividion Therapeutics Names Shawn Rose as Chief Development Officer
Vividion Therapeutics, Inc. and a wholly owned and independently operated subsidiary of Bayer AG, announced that Dr. Shawn Rose, M.D. Ph.D., has joined the company as Chief Development Officer, Immunology, reporting to our Chief Executive Officer, Aleksandra Rizo.
September 7, 2023
·
4 min read
Business
Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer
Vividion Therapeutics, Inc. today announced that Matt Patricelli, Ph.D. has been promoted to Chief Scientific Officer.
March 23, 2023
·
4 min read
1 of 71,319
Next
